Skip to content
XLenti™ Packaging Cell Lines

XLenti™ Packaging Cell Lines

XLenti™ Stable Cell Lines for Lentivirus Manufacturing: new development, characterisation, and future goals

Lentiviral vectors (LV) present huge potential for cell and gene therapy. After the first LV-engineered CAR-T cell therapies gained approval by the FDA in 2017 (Yescarta and Kymriah), more LV-based therapies are being investigated and more than 600 trials are active in the US. The demand for more efficient LV manufacturing continues to increase, but the technology still presents challenges associated with process robustness and scalability, as well as high cost-of-goods.

Download the resource to read on...

We use cookies to give you the best experience of using this website. By continuing to use this site, you accept our use of cookies. Please read our Cookie Policy for more information.

Our single technology platform that fully connects our smart labs with our customer service proposition.

Login

Connex revolutionises DNA design, optimization and assembly by ensuring the highest levels of quality control, efficiency and project management available for any client.

OXGENE has fully integrated all its smart labs and robotic production processes within a single technology platform that allows real-time project updates for our customers.